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SUMMARY 
Background: To determine the prevalence, pattern and risk factors of Diabetic Retinopathy (DR) among patients 
with Diabetes Mellitus (DM) in a tertiary hospital in north-central Nigeria. 
Settings and Design: This was a hospital-based cross-sectional study conducted in Jos, north-central Nigeria. 
Materials and Methods: Consecutive adult patients with DM attending the endocrinology clinic who consented to 
the study were examined over a six-month period. Demographic data, duration of diabetes and history of any sys-
temic disorder were obtained for each patient. A detailed ocular examination and fundus photography were per-
formed and results of blood investigations such as Fasting Blood Glucose (FBG), Glycosylated Haemoglobin 
(HbA1c) and serum lipid profile were analysed. Data analysis was done with Statistical Package for Social Sciences 
(SPSS) version 16.0 software. 
Results: Three hundred and fifty-six patients were examined comprising of 120 (33.7%) males and 236 (66.3%) 
females giving a male to female ratio of 1:2. The mean age of the study population was 56.6 ± 12.3 years. Diabetic 
retinopathy and macular oedema were present in 66 (18.5%) and 51 (14.3%) patients respectively. Diabetes diagno-
sis of 10 years and above, FBG and HbA1c all had a statistically significant association with DR with p values 
<0.001. 
Conclusion: The prevalence of DR was 18.5% in a hospital cohort of diabetic patients in north-central Nigeria with 
long duration of diabetes and poor glycaemic control being the major risk factors for retinopathy. These findings 
highlight the need for regular eye screening and good glycaemic control in individuals with diabetes in our environ-
ment.  
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INTRODUCTION 
Diabetic Retinopathy (DR) is the most common micro-
vascular complication of Diabetes Mellitus (DM) and 
the most common cause of blindness in the working-age 
population in industrialized nations.1 The World Health 
Organisation (WHO) has estimated that DR is responsi-
ble for 1% of the 39 million cases of blindness world-
wide.2 
 
 Different studies have shown considerable variability in 
the prevalence of DR among diabetic patients with rates 
ranging from 17.6% in India3 to 33.2% in the United 
States of America.4 In West Africa, the prevalence of 
DR was found to be 17.9% in patients with type 2 dia-
betes.5 Nearly 50 years ago, DR was thought to be rare 
in Nigeria with an incidence of 4.6%.6 This has in-
creased over the years with hospital-based studies now 
reporting a range of 15%-42%.7-10  
With the increasing number of people with diabetes, the 
number of DR and vision-threatening DR, which in-
cludes severe Non-proliferative Diabetic Retinopathy 
(NPDR), Proliferative Diabetic Retinopathy (PDR) and 
Diabetic Macular Oedema (DMO), has been estimated 
to rise to 191 million and 56.3 million, respectively by 
2030.11 
 
Development of DR correlates well with the duration of 
DM.12 More than 77% of patients who have had diabe-
tes for more than 20 years will have some form of reti-
nopathy.13 Thus with increasing life expectancy, DR and 
its ensuing blindness will also increase.14 The aim of 
this study, therefore, was to determine the prevalence, 
pattern and risk factors of DR among persons with DM 
attending the endocrinology clinic of a tertiary hospital 
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This would provide a data base that will aid in the plan-
ning and establishment of DR screening and treatment 
services across the region.  
 
METHODS 
This was a cross-sectional, descriptive hospital-based 
study carried out at a tertiary hospital in Jos, Plateau 
state, north-central Nigeria. The study adhered to the 
tenets of the Declaration of Helsinki and approval was 
obtained from the Ethics Committee of the hospital. The 
study population included consecutive new and old 
adult patients (≥18years) with DM seen in the endocri-
nology clinic over a period of 6 months from October 
2015 to March 2016. Patients who were not willing to 
participate in the study and patients with ocular media 
opacities that precluded posterior segment examination 
after full mydriasis were excluded. 
 
Informed consent was obtained from each patient in the 
clinic before enrolment in the study. The patient’s Fast-
ing Blood Glucose (FBG) was then measured using a 
glucometer. Laboratory tests including Glycated Hae-
moglobin (HbA1c) and serum cholesterol which were 
routinely requested for by the endocrinologists (not ex-
ceeding 3 months) were retrieved from the patients’ 
case notes. For those who did not have recent results, 
blood samples were taken for analysis at the hospital 
laboratory. As a measure of good control, FBG was 
taken as 3.9-7.0 mmol/L, HbA1c <7% and total serum 
cholesterol <5.2mmol/L.15,16  
 
The Blood Pressure (BP) was taken with the subjects 
sitting quietly after resting for a few minutes. Hyperten-
sion was defined as BP ≥140/90 mmHg.17 The weight 
and height were also measured using standard equip-
ment. The weight was recorded to the nearest 0.1kg and 
the height to the nearest 0.01m. The Body Mass Index 
(BMI) was then calculated using the formula: weight (in 
kilograms) divided by height (in meters) squared. The 
BMI was classified using the WHO standard categories 
as underweight (< 18.5 kg/m2), normal weight (18.5-
24.9 kg/m2), overweight (25.0-29.9 kg/m2) or obese (≥ 
30.0 kg/m2).18 A comprehensive ocular examination was 
performed on all the patients. The anterior segment was 
examined with a slit lamp and pupillary reaction as-
sessed with a pen torch. The pupils were then dilated 
using 1% tropicamide and 5% phenylephrine eye drops. 
Posterior segment examination involved slit lamp bio-
microscopy with a 78D lens and fundus photography.  
 
Retinopathy was considered to be present if any charac-
teristic lesion as defined by the International Clinical 
Diabetic Retinopathy Disease Severity Scale 
(ICDRDSS)19 was present: microaneurysms, haemor-
rhages, hard exudates, venous beading, intraretinal mi-
crovascular abnormalities, and new vessels. The stage 
of DR was defined as either mild, moderate, severe 
NPDR or as PDR. Macular oedema was defined accord-
ing to the International Clinical Diabetic Macular Oe-
dema Disease Severity Scale19 and includes presence of 
retinal thickening or hard exudates in the posterior pole. 
 
 Fundus photograph was taken with the Opto angiocam 
ADS 1.3 FA (Opto Electronica S/A, Sao Paulo, Brazil). 
Ocular examination was carried out by the first author. 
The data obtained was entered into Microsoft excel 
spread sheet and analysed with Statistical Package for 
Social Sciences (SPSS) version 16.0 software. Frequen-
cy distribution tables were generated for all data collect-
ed. The mean, median, range and standard deviations 
were determined for continuous variables. Qualitative 
variables were presented using tables, percentages and 
pie charts where appropriate.  
 
Tests of significance were done using Pearson’s chi-
square test and Student’s t-test. The chi square test was 
used to determine the association between qualitative 
variables (e.g. gender, control of BP, HbA1c and FBS) 
and DR while the Student’s t-test was used to determine 
the association between quantitative variables (e.g. age, 
mean FBS, total cholesterol and HbA1c) and presence 




A total of 370 diabetic patients were seen in the endo-
crinology clinic during the study period. Five patients 
refused pupillary dilatation and nine were excluded 
from the study after dilatation due to dense cataracts 
which precluded further view of the fundus. Three hun-
dred and fifty-six patients made up of 120 (33.7%) 
males and 236 (66.3%) females (male:female ratio 1:2) 
therefore, met the study criteria and had detailed ocular 
examination. Six (1.7%) patients had type 1 DM while 
the remaining 350 (98.3%) had type 2 DM. Taking the 
presence or absence of DR in at least one eye, 66 pa-
tients (129 eyes) had some form of DR, giving a preva-
lence of 18.5%. These comprised of 24 (36.4%) males 
and 42 (63.6%) females. This gender difference was not 
statistically significant (p = 0.61).  The mean age of the 
study population was 56.6 ± 12.3 years (range 21-89 
years, median 57.0 years). Majority (89.9%) of the pa-
tients were 41 years and above with 185 (52%) between 
41 and 60 years (Table 1).  
 
The mean age of patients with DR was 55.6 ± 9.9 years 
while the mean age of patients without DR was 56.6 ± 
12.8 years. This difference was not statistically signifi-
cant with a p value of 0.97. One hundred and sixty-six 
(57.2%) patients without DR had diabetes for less than 
10 years while most of the patients with DR (49, 74.2%) 
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21-30 9 (3.1) 0 9 (2.5) 12.61 0.05 
31-40 23 (7.9) 4 (6.1) 27 (7.6)   
41-50 65 (22.4) 13(19.7) 78 (21.9)   
51-60 77 (26.6) 30 (45.5) 107 
(30.1) 
  
61-70 79 (27.2) 14 (21.2) 93 (26.1)   
71-80 34 (11.7) 4 (6.1) 38 (10.7)   
≥81 3 (1.0) 1 (1.5) 4 (1.1)   





Table 2 Relationship between duration of diabetes 












0-4 99 (34.1) 11(16.7) 110 
(30.9) 
24.9 ˂0.001 
5-9 70 (24.1) 6 (9.1) 76 (21.3)   
10-14 65 (22.4) 22 
(33.3) 
87 (24.4)   
15-19 26 (9.0) 14 
(21.2) 
40 (11.2)   
20-24 19 (6.6) 9 (13.6) 28 (7.9)   
25-29 8 (2.8) 3 (4.5) 11 (3.1)   









The mean duration of diabetes was 9.53 ± 7.1 years 
(range: 0.08 to 35.0 years, median 8.0 years).  Patients 
with and without DR had a mean duration of 13.2 ± 7.0 
years and 8.7 ± 7.0 years respectively. This difference 
was statistically significant (p ˂0.001). The mean value 
for BMI (table 3) was 29.4 in patients without DR and 
27.8 in patients with DR. This difference was statistical-
ly significant (p=0.02). The mean systolic BP of the 
cohort was 134.3 ± 21.4mmHg (range 80 – 240 mmHg). 
There were 199 (55.9%) patients who had systolic BP 
˂140 mmHg. The mean diastolic blood pressure of the 
study subjects was 82.1 ± 12.2 mmHg (range 50 – 
130mmHg). A total of 214 (60.1%) patients had diastol-
ic BP ˂ 90 mmHg (Table 4). The difference in BP con-
trol in patients with and without DR was not statistically 
significant as shown in Table 4.  
 
Mean values for FBG, HbA1c and total serum choles-
terol were higher in participants who had DR. These 
differences were statistically significant for FBG 
(p˂0.001) and HbA1c (p˂0.001) as shown in Table 3. 
 
Table 3 Relationship between body mass index and 
laboratory investigations with prevalence of diabetic 
retinopathy 
Variable No DR DR T p-value 
Body mass index 29.4±5.1 27.8±4.8 2.34 0.02 
Fasting blood glu-
cose (mmol/L) 
8.3±3.3 10.3±5.1 4.06 ˂0.001 
Glycated haemo-
globin (%) 
8.7±2.7 10.5±2.7 4.87 ˂0.001 
Total cholesterol 
(mmol/L) 
5.1±1.5 5.3±1.6 1.01 0.31 
 
Table 4 Risk factors and diabetic retinopathy 








Systolic BP      
Good control 164 (56.6) 35 (53.0) 199 (55.9) 0.27 0.60 
Poor control 126 (43.4) 31 (47.0) 157 (44.1)   
Total 290 (100.0) 66 (100.0) 356 (100.0)   
Diastolic BP      
Good control 175 (60.3) 39 (59.1) 214 (60.1) 0.04 0.85 
Poor control 115 (39.7) 27 (40.9) 142 (39.9)   
Total 290 (100.0) 66 (100.0) 356 (100.0)   
BMI      
Underweight 4 (1.4) 0  4 (1.1) 4.92 0.04 
Normal 
weight 
48 (16.6) 20 (30.3) 68 (19.1)   
Overweight 113 (39,0) 25 (37.9) 138 (38,8)   
Obese 125 (43.1) 21 (31.8) 146 (41.0)   
Total 290 (100.0) 66 (100.0) 356 (100.0)   
FBG      
Good control 133 (45.9) 21 (31.8) 154 (43.3) 4.32  0.04 
Poor control 157 (54.1) 45 (68.2) 202 (56.7)   
Total 290 (100.0) 66 (100.0) 356 (100.0)   
HbA1c      
Good control 60 (20.7) 6 (9.1) 66 (18.5) 4.79 0.03 
Poor control 230 (79.3) 60 (90.0) 290 (81.5)   
Total 290 (100.0) 66 (100.0) 356 (100.0)   
Total Choles-
terol 
     
Normal 196 (67.6) 39 (59.1) 235 (66.0) 1.73 0.19 
Abnormal 94 (32.4) 27 (40.9) 121 (34.0)   
Total 290 (100.0) 66 (100.0) 356 (100.0)   
 
Of the 712 eyes of 356 patients examined, 583 (81.9%) 
had no DR, 107 (15.0%) had NPDR while 22 (3.1%) 
had PDR. Twenty-four (6.7%) patients had bilateral 
mild NPDR, 22 (6.2%) bilateral moderate NPDR, two 
(0.6%) bilateral severe NPDR and seven (1.9%) bilat-
eral PDR. Three (0.8%) patients had unilateral DR (one 
mild NPDR and two moderate NPDR) while eight had 
varying stages of DR in both eyes.  
 
Diabetic macular oedema was present in 92 (12.9%) 
eyes of 51 (14.3%) patients and was bilateral in 41 
(11.5%) patients. Forty (78.4%) of these patients with 
DMO also had associated DR. None of the six patents 
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DISCUSSION 
The mean age of the patients in this study (56.6 years) is 
in agreement with findings of similar studies in south 
west and north west Nigeria.7,9,10 For countries classified 
by the World Bank as being high-income countries, 
most people with diabetes are aged over 60 years, 
whereas for low- and middle-income countries most 
people with diabetes are of working age, between 40 
and 60 years.20 It is, therefore, not surprising to find that 
more than 50% of the patients in this study were within 
this age group. Similar to the finding by Ashaye et al10 
in Ibadan, south west Nigeria we did not find any statis-
tically significant difference between the mean age of 
patients with and without DR. 
 
The prevalence of DR in this study was 18.5%. This 
compares favourably with 20.5% reported by the Nige-
rian Blindness and Visual Impairment Survey21 and falls 
within the range of 15%-42% reported by previous hos-
pital-based studies in the country.7-10 In contrast to our 
finding, however, higher prevalence rates were reported 
in similar studies in Egypt,22 Turkey,23 and India.24 
These variations may be as a result of differences in 
sample size, classification system used to define the 
presence of DR and examination method used. Classifi-
cation of DR was done using the ICDRDSS classifica-
tion in this present study. This classification is simple to 
use, easy to remember and based on scientific evi-
dence.25 
 
About 11% of the patients with DR in this study had 
PDR. This contrasts with less than 4% reported in most 
studies in Nigeria 7,9,10 with the exception of the study 
by Nwosu8 in south east Nigeria which found a preva-
lence of 26%. In studies in Egypt,22 Turkey,23 and In-
dia,24 PDR accounted for 48%, 58% and 15% respec-
tively of cases of DR. Without treatment 50% of all 
patients with PDR will become blind within 5 years of 
diagnosis.26 Early detection and treatment is therefore 
essential as visual impairment from DR can compro-
mise patients’ ability to successfully manage their dis-
ease, resulting in a negative impact on the incidence of 
other DM complications and overall life expectancy of 
the patient.    
 
Diabetic macular oedema occurs apart from the stage of 
DR and should be evaluated independently.27 It is the 
most common cause of moderate or severe visual loss in 
diabetic patients and is invariably present in patients 
with type 2 DM with PDR.27,28 The risk factors for 
DMO are, however, largely similar to DR.28  
The prevalence of DMO in this study (14.3%) is in 
agreement with 14.8 % reported in Ekiti, south west 
Nigeria29 but contrasts with 56% reported in Nnewi, 
south east Nigeria.8 Differences in sample size may be a 
factor in this wide difference in prevalence rates of 
DMO in the country. Our observation also correlates 
well with findings in Egypt (16%)22 and India (19%).24 
Diabetic macular oedema can substantially affect inde-
pendence and quality of life of a patient as it affects 
central vision leading to decline in vision ranging from 
slight visual blurring to blindness.30  
 
There was no significant association between gender 
and DR in this study. Previous reports have shown an 
inconsistent relationship between gender and DR. Some 
studies have reported the male gender as an independent 
risk factor for DR,3,12 while others, in agreement with 
our observation did not find any statistically significant 
association between DR and gender.19,23,26,27,31,32 
 
The duration of diabetes was found to be significantly 
associated with the presence of DR in this report. This is 
consistent with findings from previous studies which 
showed that a longer diabetes duration was an inde-
pendent risk factor for DR.3,4,10,12 Long duration of dia-
betes has been described as the most important and 
strongest risk factor associated with development of 
DR.33 Diabetes duration reflects total glycaemic control 
and risk factor exposure over time.34 
 
Hypertension is another major risk factor for the devel-
opment of micro-vascular as well as macro-vascular 
complications in diabetes.35  The United Kingdom Pro-
spective Diabetes Study (UKPDS) showed that, among 
patients with type 2 DM, tight BP control resulted in a 
significant reduction in progression of DR as well as a 
significant decrease in vision loss and need for laser 
photocoagulation compared to less control.36 Most of the 
patients in this study including those with DR had 
achieved good BP control and hypertension was not 
found to be a risk factor. This is similar to the finding 
by Ashaye et al.10 
 
Hyperglycaemia is one of the most important determi-
nants of diabetic microvascular complications.37,38 The 
Chennai Urban Rural Epidemiological Study34 demon-
strated a significant increase in the prevalence of DR 
with increasing HbA1c levels while the Diabetes Con-
trol and Complications Trial (DCCT) in type 1 diabe-
tes39 and the UKPDS in type 2 diabetes40 highlighted the 
long-term benefits of glycaemic control.  
 
The DCCT in type 1 DM and UKPDS in type 2 DM 
also demonstrated that intensive glycaemic control re-
duces both the development and progression of DR, 
with the beneficial effects persisting up to 10–20 years.  
Measurement of HbA1c is considered the test of choice 
for monitoring and management of diabetes as it pro-
vides a reliable measure of chronic glycemia and corre-
lates well with the risk of long-term diabetes complica-
tions.41 We found a significant association between poor 
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This is consistent with previous reports.12,23,34 Only 
18.5% had good glycaemic control using HbA1c com-
pared to 43.3% using FBG. This disparity is probably 
due to patients becoming more compliant with their 
medications when they know they have a doctor’s ap-
pointment giving rise to a normal FBG on clinic days. 
 
A high total serum cholesterol has been shown to be 
associated with a higher prevalence of DMO.42 Estima-
tion of serum total cholesterol and lipids is therefore 
essential in DR, especially in patients with DMO. Pre-
vious studies have also demonstrated that total choles-
terol and serum low-density lipoprotein cholesterol are 
associated with the presence of hard exudates in patients 
with DR.43,44 Most of the patients in this study had good 
control of serum lipids though, patients with DR had 
higher mean serum cholesterol.  
 
The effect of obesity on DR has been relatively well-
studied but with inconclusive and conflicting findings.45 
In this present study, patients with and without DR were 
on the average overweight though the mean BMI was 
found to be higher among patients without DR. Similar-
ly, studies in south west Nigeria,10 China46 and Singa-
pore47 also found an inverse relationship between BMI 
and DR.  
 
The exact mechanisms underlying the inverse associa-
tion between BMI and DR are uncertain.48 It may not be 
that higher BMI is protective towards DR, but that indi-
viduals with lower BMI may have more severe DM (as 
patients with decompensated disease may undergo a 
catabolic phase resulting in unintentional weight loss) 
and thus have a higher risk of developing DR.48  Lu et al 
also attributed this inverse relationship to better pancre-
atic β-cell function in overweight individuals.46 In con-
trast to our observation, however, studies in Turkey23 
and Australia49 found obesity to be an independent risk 
factor for DR with persons with higher BMI being more 
likely to have DR and more severe stages of DR.  
 
The effect of obesity may be due to its correlation with 
HbA1c and systolic BP. Katusić et al50 observed a sig-
nificant deterioration of HbA1c and a significant in-
crease in low density lipoprotein-cholesterol, systolic 
and diastolic BP with increase in BMI. The observation 
of a lower prevalence of DR in patients with a higher 
BMI in this study should therefore, be interpreted with 
caution as overweight and obesity have been associated 
with many health risks including DM as well as overall 
mortality.48,51,52 
 
A limitation of this study was our inability to do optical 
coherence tomography and Fundus Fluorescein Angi-
ography (FFA) due to lack of necessary equipment.  
 
Optical coherence tomography would have been helpful 
in evaluating the macula for oedema while FFA would 
have assisted in determining the presence or absence of 




Poor glycaemic control and duration of diabetes were 
the major risk factors for DR in our study.  These find-
ings further stress the need for regular screening for DR 
and good glycaemic control in individuals with diabetes 
in our environment.  
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